NYSE · ANRO
Alto Neuroscience, Inc.
$23.47+$0.14 (+0.6%)
Alto Neuroscience, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.38% below the high.
Loading market information…
NASDAQ · LRMR · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Larimar Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.41% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Larimar Therapeutics, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.35. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Larimar Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Mar 24, 2025 |
| -$0.45-55.17% vs estimate |
| $241.00K |
| Q3 2024 | Oct 30, 2024 | -$0.24+35.14% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $8.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$23.47+$0.14 (+0.6%)
Alto Neuroscience, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.38% below the high.
$4.01-$0.03 (-0.74%)
Annexon, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.15% below the high.
$2.14+$0.04 (+1.9%)
Altimmune, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.77% below the high.
$5.85-$0.04 (-0.68%)
Kyverna Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.21% below the high.
$12.74-$0.01 (-0.08%)
Amarin Corporation plc’s quoted price sits in the lower half of its reported 52-week range, 26.43% below the high.
$3.06-$0.07 (-2.24%)
Lexeo Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 72.16% below the high.
$10.29-$0.36 (-3.38%)
DBV Technologies S.A.’s quoted price sits in the lower half of its reported 52-week range, 60.71% below the high.
$2.37$0.00 (0.0%)
AC Immune S.A.’s quoted price sits in the lower half of its reported 52-week range, 39.23% below the high.
